Brandon Vazquez

Matthew O'Brien

Richard Newitter

Christopher Pasquale

Craig Bijou

Joshua Jennings

Nathan Treybeck

Patrick Wood

Ryan Zimmerman

Michael Kratky

Michael Sarcone

Mike Kratky

Chris Pasquale

Josh Jennings

Mason Carrico

Suraj Kalia

- PROCEPT (PRCT) reported **Q3 2025 total revenue of $83.3 million**, representing **43% growth** compared to Q3 2024, primarily driven by **U.S. capital system sales totaling $58 million**.  **[0001588978_2233327_1]** **[0001588978_2233327_3]** 
- The company maintained its **full-year 2025 total revenue guidance of $325.5 million** and an **Adjusted EBITDA loss of $35 million**, but adjusted Q4 handpiece sales guidance downwards due to field inventory optimization.  **[0001588978_2233327_3]** **[0001588978_2233327_17]** 
- For **fiscal 2026, PROCEPT anticipates total revenue in the range of $410-$430 million**, reflecting current momentum in capital sales and expected modest procedural headwinds in the first half.  **[0001588978_2233327_4]** **[0001588978_2233327_9]** 
- Management is implementing organizational changes and initiatives to **improve procedure utilization** and the speed of new account launches, while also increasing investment in international markets.  **[0001588978_2233327_1]** **[0001588978_2233327_7]**

PRCT Reports Strong Q3 2025 Revenue and Provides Preliminary 2026 Guidance

- **PROCEPT BioRobotics** reported **total revenue of $83.3 million** for the third quarter of 2025, an increase of **43%** compared to the prior year period.  **[1588978_338ef4dca9e542e2a015451a6e45c34c_0]** **[1588978_338ef4dca9e542e2a015451a6e45c34c_1]** 
- The company reiterated its fiscal year 2025 total revenue guidance of approximately **$325.5 million** and issued fiscal year 2026 total revenue guidance in the range of **$410 million to $430 million**.  **[1588978_338ef4dca9e542e2a015451a6e45c34c_0]** **[1588978_338ef4dca9e542e2a015451a6e45c34c_2]** **[1588978_338ef4dca9e542e2a015451a6e45c34c_3]** 
- For the third quarter of 2025, the **gross margin was 65%**, the **net loss was $21.4 million**, and the **Adjusted EBITDA loss was $7.4 million**.  **[1588978_338ef4dca9e542e2a015451a6e45c34c_1]** **[1588978_338ef4dca9e542e2a015451a6e45c34c_6]** **[1588978_338ef4dca9e542e2a015451a6e45c34c_7]**

PROCEPT BioRobotics Reports Q3 2025 Financial Results and Issues 2026 Revenue Guidance

- **PROCEPT BioRobotics** reported **total revenue of $83.3 million** for the third quarter of 2025, an increase of **43%** compared to the prior year period.  **[1588978_0001588978-25-000049_prct_q32025earningsrelease.htm:0]** 
- The **U.S. install base** grew by **58 robotic systems** in Q3 2025, bringing the total to **653 systems** as of September 30, 2025.  **[1588978_0001588978-25-000049_prct_q32025earningsrelease.htm:0]** 
- **Gross margin** for Q3 2025 improved to **65%** (from 63% in Q3 2024), and **Adjusted EBITDA loss** narrowed to **$7.4 million** (from $12.4 million in Q3 2024).  **[1588978_0001588978-25-000049_prct_q32025earningsrelease.htm:0]** 
- The company maintained its **fiscal year 2025 total revenue guidance** at approximately **$325.5 million**, representing **45% growth** over the prior year.  **[1588978_0001588978-25-000049_prct_q32025earningsrelease.htm:0]** **[1588978_0001588978-25-000049_prct_q32025earningsrelease.htm:1]** 
- **Fiscal year 2026 total revenue guidance** was issued in the range of **$410 million to $430 million**, indicating **26% to 32% growth** over the 2025 guidance.  **[1588978_0001588978-25-000049_prct_q32025earningsrelease.htm:0]** **[1588978_0001588978-25-000049_prct_q32025earningsrelease.htm:1]**

PROCEPT BioRobotics Reports Strong Q3 2025 Results and Issues 2026 Revenue Guidance

PROCEPT BioRobotics (PRCT)